Modification of PAR-10-184: NIAID Clinical Trial Implementation Grant (R01)


Notice Number: NOT-AI-11-026

Key Dates

Release Date:   January 3, 2011

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to announce a substantive change to requirements articulated in PAR-10-184: NIAID Clinical Trial Implementation Grant (R01).  

In Section I, 1. Research Objectives, the "Scope" section of PAR-10-184:

Delete "include a randomized design" from the sentence that reads: "The trial must be hypothesis- driven, include a randomized design, and have clear primary and secondary endpoints."

Randomization is only required for those trials for which it is an appropriate element of trial design.

All other aspects of  PAR-10-184 remain unchanged.

Inquiries

Please direct all inquiries to:

Anna Ramsey-Ewing, Ph.D.
Associate Director for Extramural Science Policy
Office of the Director   
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
6700-B Rockledge Drive, MSC 7610
Bethesda, MD 20892-7610
Phone: (301) 435-8536
FAX: (301) 402-0369
E-mail:  ar15o@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.